Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases (IBD) Including Drug Levels: a Multi-center Prospective Cohort Study, From the Pediatric IBD Porto Group of European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)

NCT02862132 is registered in ClinicalTrials.gov with Shaare Zedek Medical Center as lead sponsor.

NCT NCT02862132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02862132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases (IBD) Including Drug Levels: a Multi-center Prospective Cohort Study, From the Pediatric IBD Porto Group of European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)
Lead sponsor
Shaare Zedek Medical Center
Phase
Not applicable
Overall status
Completed
Start date
January 31, 2017
Completion date
January 31, 2022
Enrollment
142 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease, inflammatory bowel disease, ulcerative colitis